Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 3, 2026Indian Journal of Pharmacology

Prasugrel-based DAPT is linked to greater hs-CRP reduction vs clopidogrel in ACS patients undergoing PCI.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does prasugrel plus aspirin reduce inflammatory and oxidative stress markers compared to clopidogrel plus aspirin in ACS patients undergoing PCI?

Population

104 enrolled patients aged 18-65 years with acute coronary syndrome undergoing percutaneous coronary…

Comparison

Prasugrel added to aspirin (AP group) vs Clopidogrel added to aspirin (AC group)

Design

Cohort

Follow-up

4 weeks

Key result

Prasugrel-based DAPT showed a significantly greater reduction in hs-CRP levels at 4 weeks compared to clopidogrel-based DAPT (-7.17 vs -4.10 mg/L, P=0.002) in ACS patients undergoing PCI.

Authors

SVShanmugapriya VinayagamNMNiti MittalAKAshwani Kumar

Discussion

Loading...

Member takes

Overview

Prasugrel-based DAPT provides greater anti-inflammatory benefits than clopidogrel-based DAPT in ACS patients undergoing PCI, suggesting additional pleiotropic effects.

Key Points

  • To compare the anti-inflammatory and antioxidant pleiotropic effects of clopidogrel versus prasugrel in dual antiplatelet therapy among patients undergoing percutaneous coronary intervention for acute coronary syndrome.
  • Conducted a prospective cohort study of 104 patients aged 18–65 years undergoing percutaneous coronary intervention for acute coronary syndrome.
  • Assigned participants to dual antiplatelet therapy consisting of aspirin plus clopidogrel (n = 52) or aspirin plus prasugrel (n = 52).
  • Evaluated changes in high-sensitivity C-reactive protein (hs-CRP) and total antioxidant capacity (TAOC) from baseline to 4 weeks follow-up.
  • The prasugrel group demonstrated a significantly greater reduction in hs-CRP levels at 4 weeks compared to the clopidogrel group (−7.17 ± 5.95 mg/L vs. −4.10 ± 3.81 mg/L, P = 0.002; n = 90 analyzed).
  • Total antioxidant capacity increased to a greater extent with prasugrel than clopidogrel, though the difference was not statistically significant (184.25 ± 274.03 vs. 126.67 ± 198.49, P = 0.117).
  • Bleeding incidents and adverse event rates were comparable between the two treatment cohorts.

Study Design

Type

Cohort (n=90)

Structured PICO

Does prasugrel plus aspirin reduce inflammatory and oxidative stress markers compared to clopidogrel plus aspirin in ACS patients undergoing PCI?

P
Population
90 patients aged 18-65 years undergoing PCI for acute coronary syndrome, followed for 4 weeks.
E
Exposure
Prasugrel added to aspirin (AP group)
C
Comparator
Clopidogrel added to aspirin (AC group)
O
Outcome
Change in inflammatory marker (high-sensitivity C-reactive protein [hs-CRP]) and oxidative stress marker (total antioxidant capacity [TAOC]) at 4 weeks compared to baselinesurrogate

Main Result

Absolute Event Rate: -7.17% vs -4.1%

p-value: p=0.002

Prasugrel-based DAPT provides greater anti-inflammatory benefits than clopidogrel-based DAPT in ACS patients undergoing PCI, suggesting additional pleiotropic effects.

Cite This Study

Vinayagam et al. (2026) conducted a cohort in Acute coronary syndrome (n=90). Prasugrel vs. Clopidogrel was evaluated on Change in high-sensitivity C-reactive protein (hs-CRP) at 4 weeks (p=0.002). Prasugrel-based DAPT showed a significantly greater reduction in hs-CRP levels at 4 weeks compared to clopidogrel-based DAPT (-7.17 vs -4.10 mg/L, P=0.002) in ACS patients undergoing PCI.

synapsesocial.com/papers/6a993635636c6408cfa7f17ehttps://doi.org/10.4103/ijp.ijp_3_26
View Full Paper
Ask AI
Bookmark
Share